What is Positron?
Positron Corporation operates at the intersection of advanced medical diagnostics and nuclear medicine. The company is primarily recognized for its Attrius system, a sophisticated cardiac PET imaging platform designed to improve patient outcomes through high-precision molecular imaging. Beyond hardware, Positron maintains a vertically integrated business model that includes the processing and production of radioisotopes, specifically focusing on the supply of Sr-82. This dual-focus approach—combining high-end diagnostic equipment with essential medical supply chain management—positions the company as a critical partner for cardiology departments and healthcare facilities seeking to implement cost-effective, high-accuracy diagnostic protocols.
How much funding has Positron raised?
Positron has raised a total of $33.6M across 4 funding rounds:
Debt
$66K
Multiple Rounds
$33.5M
Debt (2021): $66K with participation from PPP
Angel/Seed (2025): $23.5M led by Valor Equity Partners, Flume Ventures, and Atreides Management
Share Placement (2025): $8M, investors not publicly disclosed
Stock/Share Issuance (2025): $2M, investors not publicly disclosed
Key Investors in Positron
Valor Equity Partners
Valor Equity Partners provides financial services to businesses in the scope of investment activities. This company is headquartered in Chicago, Illinois and was established in 2001.
Flume Ventures
Flume Ventures is a network of seasoned operators and founders dedicated to partnering with visionary entrepreneurs to scale bold ideas through strategic support and mentorship.
Atreides Management
Founded in 2019 and headquartered in Boston, Massachusetts, Atreides Management is a company that focuses on long-term investment for companies in the technology and consumer businesses in both public and private markets.
What's next for Positron?
With the successful closure of this major strategic investment, Positron is expected to accelerate its operational roadmap, focusing on the expansion of its Sr-82 supply chain and the broader deployment of its Attrius technology. The company's strategic focus remains on addressing the growing demand for non-invasive cardiac diagnostics, a sector that continues to see increased investment as healthcare systems prioritize early detection and preventative care. Moving forward, the firm will likely leverage its strengthened balance sheet to pursue further research and development initiatives, potentially exploring new frontiers in radiopharmaceutical production and automated imaging systems to maintain its competitive edge in the global nuclear medicine market.
See full Positron company page
